GSK PLC (GSK)
39.27
-0.33
(-0.83%)
USD |
NYSE |
Apr 18, 16:00
39.28
+0.01
(+0.03%)
Pre-Market: 20:00
GSK Cash from Financing (TTM): -7.019B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.019B |
| September 30, 2023 | -4.119B |
| June 30, 2023 | -3.724B |
| March 31, 2023 | -10.06B |
| December 31, 2022 | 1.019B |
| September 30, 2022 | -1.258B |
| June 30, 2022 | -1.275B |
| March 31, 2022 | 2.153B |
| December 31, 2021 | -10.44B |
| September 30, 2021 | -9.360B |
| June 30, 2021 | -13.22B |
| March 31, 2021 | -13.55B |
| December 31, 2020 | -13.00B |
| September 30, 2020 | -13.76B |
| June 30, 2020 | -10.47B |
| March 31, 2020 | -8.467B |
| December 31, 2019 | -2.349B |
| September 30, 2019 | -3.298B |
| June 30, 2019 | -2.959B |
| March 31, 2019 | -3.362B |
| December 31, 2018 | -8.524B |
| September 30, 2018 | -8.244B |
| June 30, 2018 | -7.082B |
| March 31, 2018 | -6.762B |
| December 31, 2017 | -8.238B |
| Date | Value |
|---|---|
| September 30, 2017 | -6.905B |
| June 30, 2017 | -8.255B |
| March 31, 2017 | -8.650B |
| December 31, 2016 | -8.661B |
| September 30, 2016 | -7.189B |
| June 30, 2016 | -8.109B |
| March 31, 2016 | -10.03B |
| December 31, 2015 | -10.86B |
| September 30, 2015 | -12.17B |
| June 30, 2015 | -9.230B |
| March 31, 2015 | -7.294B |
| December 31, 2014 | -8.877B |
| September 30, 2014 | -8.809B |
| June 30, 2014 | -10.32B |
| March 31, 2014 | -11.84B |
| December 31, 2013 | -9.815B |
| September 30, 2013 | -8.822B |
| June 30, 2013 | -8.969B |
| March 31, 2013 | -5.613B |
| December 31, 2012 | -5.310B |
| September 30, 2012 | -5.746B |
| June 30, 2012 | -6.758B |
| March 31, 2012 | -9.850B |
| December 31, 2011 | -9.993B |
| September 30, 2011 | -9.493B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-13.76B
Minimum
Sep 2020
2.153B
Maximum
Mar 2022
-6.588B
Average
-7.019B
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
| AstraZeneca PLC | -6.567B |
| Haleon PLC | -- |
| Novo Nordisk A/S | -9.170B |
| Pfizer Inc | 26.07B |
| Sanofi SA | -- |